1185293-45-1

Basic information

• Product Name: 1-METHYL-2-PHENYL-PIPERAZINE DIHYDROCHLORIDE
• Synonyms: 1-METHYL-2-PHENYL-PIPERAZINE DIHYDROCHLORIDE
• CAS NO: 1185293-45-1
• Molecular Formula: C11H18Cl2N2
• Molecular Weight: 249.18
• Mol File: 1185293-45-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-METHYL-2-PHENYL-PIPERAZINE DIHYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-2-PHENYL-PIPERAZINE DIHYDROCHLORIDE(1185293-45-1)
• EPA Substance Registry System: 1-METHYL-2-PHENYL-PIPERAZINE DIHYDROCHLORIDE(1185293-45-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 1185293-45-1(Hazardous Substances Data)

Usage

General Description

1-Methyl-2-phenyl-piperazine dihydrochloride is a chemical compound that belongs to the class of piperazine derivatives. It is a white crystalline powder that is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. 1-METHYL-2-PHENYL-PIPERAZINE DIHYDROCHLORIDE has been studied for its potential therapeutic uses in the treatment of various medical conditions, including depression and anxiety disorders. It is also used in research and development as a building block for the synthesis of new drug candidates. Additionally, 1-methyl-2-phenyl-piperazine dihydrochloride is utilized in chemical and biochemical applications as a reagent and catalyst.

Upstream product

• 5271-26-1 m-phenylpiperazine 
• 502649-25-4 tert-butyl 4-(3-methoxy-4-(1H-pyrazol-4-yl)benzoyl)-3-phenylpiperazine-1-carboxylate 
• 1598383-11-9 4-methyl-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1598383-12-0 (S)-1,1,1-trifluoro-3-(4-methyl-3-phenyl-piperazin-1-yl)-propan-2-ol 

Relevant articles and documents

Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists

The P2X7 receptor (P2X7R) stands out among the purinergic receptors due to its strong involvement in the regulation of tumor growth and metastasis formation as well as in innate immune responses and afferent signal transmission. Numerous studies have pointed out the beneficial effects of P2X7R antagonism for the treatment of a variety of cancer types, inflammatory diseases, and chronic pain. Herein we describe the development of novel P2X7R antagonists, incorporating piperazine squaric diamides as a central element. Besides improving the antagonists’ potency from pIC50 values of 5.7–7.6, ADME properties (logD7.4 value, plasma protein binding, in vitro metabolic stability) of the generated compounds were investigated and optimized to provide novel P2X7R antagonists with drug-like properties. Furthermore, docking studies revealed the antagonists binding to the allosteric binding pocket in two distinct binding poses, depending on the substitution of the central piperazine moiety.

Heterocyclic derivatives as HDAC inhibitors

This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6/sub